Macrogenics Inc Stock Price, News & Analysis

MacroGenics (Nasdaq: MGNX) announced its participation in two investor conferences in March 2022. The first event is the Cowen 42^nd Annual Health Care Conference on March 8, where CEO Scott Koenig will join a panel discussion at 10:30 AM ET. The second is the Barclays Global Healthcare Conference on March 15, featuring a corporate overview at 3:50 PM ET. Both events will include one-on-one meetings and webcasts accessible via MacroGenics' investor relations website, with archived replays available for 30 days.

MacroGenics, Inc. (NASDAQ: MGNX) has promoted Eric Risser to Chief Operating Officer, effective February 22, 2022. Risser has been with the company since 2009, significantly contributing to collaboration partnerships, business development, and program management. He previously served as Senior Vice President and Chief Business Officer. The promotion reflects the company's confidence in his leadership abilities to drive product advancements and shareholder value. MacroGenics focuses on developing innovative antibody-based therapeutics for cancer treatment, leveraging advanced technology platforms.

MacroGenics, Inc. (MGNX) has launched a Phase 1 dose escalation study of MGC018 in combination with lorigerlimab, focusing on B7-H3-directed therapies for treating solid tumors. The company plans to meet the FDA to discuss a registration-directed study for MGC018 in metastatic castration-resistant prostate cancer (mCRPC). Financially, MacroGenics reported $77.4 million in revenue for 2021, a decline from $104.9 million in 2020. The net loss widened to $202.1 million, compared to $129.7 million in the previous year. The company maintains a cash runway through 2023.

MacroGenics, a biopharmaceutical company focused on monoclonal antibody therapeutics for cancer, will release its fourth quarter financial results for 2021 on February 24, 2022, after the market closes. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and corporate progress. Investors can access the call by dialing (877) 303-6253 domestically or (973) 409-9610 internationally, with a Conference ID of 1067087. A webcast will also be available on the company's website.

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focusing on monoclonal antibody-based therapies for cancer, will participate in several upcoming virtual conferences in February 2022. Notable events include:

• Guggenheim Healthcare Talks on February 10, 2022, at 9:00 am ET.
• Citi’s 2022 Virtual Immuno-Oncology Summit on February 17, 2022, at 12:30 pm ET.
• 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:40 am ET.

Archived webcasts will be available on MacroGenics' website.

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company, announced its participation in several healthcare conferences in November and December 2021. Key events include:

• Credit Suisse 30th Annual Healthcare Conference: November 9, 2021, at 8:00 am ET.
• Stifel 2021 Virtual Healthcare Conference: November 16, 2021, at 8:00 am ET.
• Evercore ISI HealthCONx Virtual Conference: December 2, 2021, at 8:25 am ET.
• JMP Securities Hematology and Oncology Summit: December 6, 2021, at 1:00 pm ET.

Webcasts of these presentations will be available on their website.

MacroGenics, Inc. (NASDAQ: MGNX) has submitted an IND application for MGD024, a bispecific DART molecule targeting CD123 and CD3 for AML. The FDA approved its GMP manufacturing facility for MARGENZA drug substance. However, enrollment for Cohort A of the Phase 2/3 MAHOGANY study of margetuximab is being discontinued. Financial results for Q3 2021 revealed total revenue of $15.7 million, down from $18.3 million in Q3 2020. R&D expenses rose to $49.8 million, leading to a net loss of $52.9 million. The company expects its cash position to fund operations through 2023.

MacroGenics, Inc. (Nasdaq: MGNX) will release its third-quarter 2021 financial results after the market closes on November 2, 2021. A conference call to discuss these results and recent corporate developments will be held on the same date at 4:30 pm ET. Investors can join the call by dialing the appropriate access numbers five minutes prior to the start. The presentation will also be available via a listen-only webcast on the company's Investor Relations website, with a recorded replay accessible for 30 days post-call.

MacroGenics announced promising interim results from Part 1 of the Phase 2/3 MAHOGANY clinical trial for margetuximab, targeting HER2+ gastric cancer. Out of 40 evaluated patients, 21 achieved confirmed responses, exceeding the trial's futility boundaries. The combination therapy demonstrated a 78% tumor shrinkage rate and a median response duration of 10.3 months. The treatment was well tolerated, with only 19% experiencing Grade 3 adverse events. These findings support advancing to Part 2 of the trial, with potential implications for first-line treatment options.